JOURNAL OF AUTOIMMUNITY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2229648, encodeId=a7a72229648e0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：自身免疫性疾病 经验分享：投的review，非常快，体验感很好。7.16号投稿，7.22号送审，7.30号送审结束，两个审稿人意见，8.6号大修，9.3号提交response，9.8号返修来自两个审稿人的小修意见，9.12号提交response，9.13号回复小修，9.24号提交response，9.26号接受，当天proof，9.28号见刊。神速~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb785144048, createdName=14681332m54(暂无昵称), createdTime=Mon Oct 07 14:15:00 CST 2024, time=2024-10-07, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2231090, encodeId=268b2231090f8, content=请问各位大佬，这个期刊with editor 后状态变成decision in process 是不是就是要拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=461a2103235, createdName=1521f6f9dcm, createdTime=Tue Oct 15 19:39:47 CST 2024, time=2024-10-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2197439, encodeId=fa4c219e4396e, content=偏重的研究方向：哮喘;巨噬细胞 经验分享：来积攒人品。3月21日提交，3月22日with editor ，4月6日decision in process,目前还是decision in process, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fed15185369, createdName=14706479m35(暂无昵称), createdTime=Mon Apr 08 19:19:48 CST 2024, time=2024-04-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2200114, encodeId=d48a2200114a5, content=4.4号投稿，4.5号with editor 4.18号还是with editor , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e884788237, createdName=mxy268133mxy, createdTime=Wed Apr 24 12:19:18 CST 2024, time=2024-04-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1217049, encodeId=239f121e049dd, content=有没有人可以分享一下投稿进程？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a9b85535861, createdName=Mis 吴, createdTime=Thu May 05 14:06:39 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192591, encodeId=259b219259102, content=偏重的研究方向：免疫 经验分享：2024.03.08 submitted to journal 2024.03.08 with editor 投稿时忘记上传WB 的原始图片PDF了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Mar 11 15:27:07 CST 2024, time=2024-03-11, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2193998, encodeId=f568219399892, content=提交到期刊近20天没有变化，杂志首页却介绍首个决定5天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/n4IYDdvYfkjeLr8oiaPal0dQa93Zgia4eCSXxEJrEoviaPdbED0F1HbgT84Xfl8v7mTjsHNkG5sK8fxVjBrU4N8XQ/132, createdBy=00212440140, createdName=ms3236964720522021, createdTime=Tue Mar 19 08:56:09 CST 2024, time=2024-03-19, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2178587, encodeId=89a521e85875b, content=请问各位大佬，jornal of autoimmunity投稿对摘要和全文没有字数要求吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7be6461276, createdName=ms3000000202046104, createdTime=Mon Jan 01 14:08:20 CST 2024, time=2024-01-01, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2174377, encodeId=290a21e4377e3, content=有哪位大神可以告知一下，为什么投稿第二步，attach files 总过不去，也上传文件了，就是不行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e759104536, createdName=ms7000001739408141, createdTime=Tue Dec 12 07:08:18 CST 2023, time=2023-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=569627, encodeId=b9dd56962ea6, content=综述要约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce9a2150313, createdName=138200c9a8m, createdTime=Wed Apr 17 00:00:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]

2024-10-07 14681332m54(暂无昵称) 来自安徽省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：自身免疫性疾病
经验分享：投的review，非常快，体验感很好。7.16号投稿，7.22号送审，7.30号送审结束，两个审稿人意见，8.6号大修，9.3号提交response，9.8号返修来自两个审稿人的小修意见，9.12号提交response，9.13号回复小修，9.24号提交response，9.26号接受，当天proof，9.28号见刊。神速~

87 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2229648, encodeId=a7a72229648e0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：自身免疫性疾病 经验分享：投的review，非常快，体验感很好。7.16号投稿，7.22号送审，7.30号送审结束，两个审稿人意见，8.6号大修，9.3号提交response，9.8号返修来自两个审稿人的小修意见，9.12号提交response，9.13号回复小修，9.24号提交response，9.26号接受，当天proof，9.28号见刊。神速~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb785144048, createdName=14681332m54(暂无昵称), createdTime=Mon Oct 07 14:15:00 CST 2024, time=2024-10-07, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2231090, encodeId=268b2231090f8, content=请问各位大佬，这个期刊with editor 后状态变成decision in process 是不是就是要拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=461a2103235, createdName=1521f6f9dcm, createdTime=Tue Oct 15 19:39:47 CST 2024, time=2024-10-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2197439, encodeId=fa4c219e4396e, content=偏重的研究方向：哮喘;巨噬细胞 经验分享：来积攒人品。3月21日提交，3月22日with editor ，4月6日decision in process,目前还是decision in process, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fed15185369, createdName=14706479m35(暂无昵称), createdTime=Mon Apr 08 19:19:48 CST 2024, time=2024-04-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2200114, encodeId=d48a2200114a5, content=4.4号投稿，4.5号with editor 4.18号还是with editor , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e884788237, createdName=mxy268133mxy, createdTime=Wed Apr 24 12:19:18 CST 2024, time=2024-04-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1217049, encodeId=239f121e049dd, content=有没有人可以分享一下投稿进程？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a9b85535861, createdName=Mis 吴, createdTime=Thu May 05 14:06:39 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192591, encodeId=259b219259102, content=偏重的研究方向：免疫 经验分享：2024.03.08 submitted to journal 2024.03.08 with editor 投稿时忘记上传WB 的原始图片PDF了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Mar 11 15:27:07 CST 2024, time=2024-03-11, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2193998, encodeId=f568219399892, content=提交到期刊近20天没有变化，杂志首页却介绍首个决定5天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/n4IYDdvYfkjeLr8oiaPal0dQa93Zgia4eCSXxEJrEoviaPdbED0F1HbgT84Xfl8v7mTjsHNkG5sK8fxVjBrU4N8XQ/132, createdBy=00212440140, createdName=ms3236964720522021, createdTime=Tue Mar 19 08:56:09 CST 2024, time=2024-03-19, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2178587, encodeId=89a521e85875b, content=请问各位大佬，jornal of autoimmunity投稿对摘要和全文没有字数要求吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7be6461276, createdName=ms3000000202046104, createdTime=Mon Jan 01 14:08:20 CST 2024, time=2024-01-01, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2174377, encodeId=290a21e4377e3, content=有哪位大神可以告知一下，为什么投稿第二步，attach files 总过不去，也上传文件了，就是不行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e759104536, createdName=ms7000001739408141, createdTime=Tue Dec 12 07:08:18 CST 2023, time=2023-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=569627, encodeId=b9dd56962ea6, content=综述要约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce9a2150313, createdName=138200c9a8m, createdTime=Wed Apr 17 00:00:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]

2024-10-15 1521f6f9dcm 来自江苏省

请问各位大佬，这个期刊with editor 后状态变成decision in process 是不是就是要拒稿了

91 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2229648, encodeId=a7a72229648e0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：自身免疫性疾病 经验分享：投的review，非常快，体验感很好。7.16号投稿，7.22号送审，7.30号送审结束，两个审稿人意见，8.6号大修，9.3号提交response，9.8号返修来自两个审稿人的小修意见，9.12号提交response，9.13号回复小修，9.24号提交response，9.26号接受，当天proof，9.28号见刊。神速~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb785144048, createdName=14681332m54(暂无昵称), createdTime=Mon Oct 07 14:15:00 CST 2024, time=2024-10-07, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2231090, encodeId=268b2231090f8, content=请问各位大佬，这个期刊with editor 后状态变成decision in process 是不是就是要拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=461a2103235, createdName=1521f6f9dcm, createdTime=Tue Oct 15 19:39:47 CST 2024, time=2024-10-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2197439, encodeId=fa4c219e4396e, content=偏重的研究方向：哮喘;巨噬细胞 经验分享：来积攒人品。3月21日提交，3月22日with editor ，4月6日decision in process,目前还是decision in process, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fed15185369, createdName=14706479m35(暂无昵称), createdTime=Mon Apr 08 19:19:48 CST 2024, time=2024-04-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2200114, encodeId=d48a2200114a5, content=4.4号投稿，4.5号with editor 4.18号还是with editor , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e884788237, createdName=mxy268133mxy, createdTime=Wed Apr 24 12:19:18 CST 2024, time=2024-04-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1217049, encodeId=239f121e049dd, content=有没有人可以分享一下投稿进程？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a9b85535861, createdName=Mis 吴, createdTime=Thu May 05 14:06:39 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192591, encodeId=259b219259102, content=偏重的研究方向：免疫 经验分享：2024.03.08 submitted to journal 2024.03.08 with editor 投稿时忘记上传WB 的原始图片PDF了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Mar 11 15:27:07 CST 2024, time=2024-03-11, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2193998, encodeId=f568219399892, content=提交到期刊近20天没有变化，杂志首页却介绍首个决定5天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/n4IYDdvYfkjeLr8oiaPal0dQa93Zgia4eCSXxEJrEoviaPdbED0F1HbgT84Xfl8v7mTjsHNkG5sK8fxVjBrU4N8XQ/132, createdBy=00212440140, createdName=ms3236964720522021, createdTime=Tue Mar 19 08:56:09 CST 2024, time=2024-03-19, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2178587, encodeId=89a521e85875b, content=请问各位大佬，jornal of autoimmunity投稿对摘要和全文没有字数要求吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7be6461276, createdName=ms3000000202046104, createdTime=Mon Jan 01 14:08:20 CST 2024, time=2024-01-01, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2174377, encodeId=290a21e4377e3, content=有哪位大神可以告知一下，为什么投稿第二步，attach files 总过不去，也上传文件了，就是不行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e759104536, createdName=ms7000001739408141, createdTime=Tue Dec 12 07:08:18 CST 2023, time=2023-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=569627, encodeId=b9dd56962ea6, content=综述要约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce9a2150313, createdName=138200c9a8m, createdTime=Wed Apr 17 00:00:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]

2024-04-08 14706479m35(暂无昵称) 来自山东省

偏重的研究方向：哮喘;巨噬细胞
经验分享：来积攒人品。3月21日提交，3月22日with editor ，4月6日decision in process,目前还是decision in process

171 14 举报

展开14条回复

[GetPortalCommentsPageByObjectIdResponse(id=2229648, encodeId=a7a72229648e0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：自身免疫性疾病 经验分享：投的review，非常快，体验感很好。7.16号投稿，7.22号送审，7.30号送审结束，两个审稿人意见，8.6号大修，9.3号提交response，9.8号返修来自两个审稿人的小修意见，9.12号提交response，9.13号回复小修，9.24号提交response，9.26号接受，当天proof，9.28号见刊。神速~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb785144048, createdName=14681332m54(暂无昵称), createdTime=Mon Oct 07 14:15:00 CST 2024, time=2024-10-07, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2231090, encodeId=268b2231090f8, content=请问各位大佬，这个期刊with editor 后状态变成decision in process 是不是就是要拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=461a2103235, createdName=1521f6f9dcm, createdTime=Tue Oct 15 19:39:47 CST 2024, time=2024-10-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2197439, encodeId=fa4c219e4396e, content=偏重的研究方向：哮喘;巨噬细胞 经验分享：来积攒人品。3月21日提交，3月22日with editor ，4月6日decision in process,目前还是decision in process, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fed15185369, createdName=14706479m35(暂无昵称), createdTime=Mon Apr 08 19:19:48 CST 2024, time=2024-04-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2200114, encodeId=d48a2200114a5, content=4.4号投稿，4.5号with editor 4.18号还是with editor , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e884788237, createdName=mxy268133mxy, createdTime=Wed Apr 24 12:19:18 CST 2024, time=2024-04-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1217049, encodeId=239f121e049dd, content=有没有人可以分享一下投稿进程？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a9b85535861, createdName=Mis 吴, createdTime=Thu May 05 14:06:39 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192591, encodeId=259b219259102, content=偏重的研究方向：免疫 经验分享：2024.03.08 submitted to journal 2024.03.08 with editor 投稿时忘记上传WB 的原始图片PDF了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Mar 11 15:27:07 CST 2024, time=2024-03-11, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2193998, encodeId=f568219399892, content=提交到期刊近20天没有变化，杂志首页却介绍首个决定5天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/n4IYDdvYfkjeLr8oiaPal0dQa93Zgia4eCSXxEJrEoviaPdbED0F1HbgT84Xfl8v7mTjsHNkG5sK8fxVjBrU4N8XQ/132, createdBy=00212440140, createdName=ms3236964720522021, createdTime=Tue Mar 19 08:56:09 CST 2024, time=2024-03-19, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2178587, encodeId=89a521e85875b, content=请问各位大佬，jornal of autoimmunity投稿对摘要和全文没有字数要求吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7be6461276, createdName=ms3000000202046104, createdTime=Mon Jan 01 14:08:20 CST 2024, time=2024-01-01, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2174377, encodeId=290a21e4377e3, content=有哪位大神可以告知一下，为什么投稿第二步，attach files 总过不去，也上传文件了，就是不行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e759104536, createdName=ms7000001739408141, createdTime=Tue Dec 12 07:08:18 CST 2023, time=2023-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=569627, encodeId=b9dd56962ea6, content=综述要约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce9a2150313, createdName=138200c9a8m, createdTime=Wed Apr 17 00:00:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]

2024-04-24 mxy268133mxy 来自浙江省

4.4号投稿，4.5号with editor 4.18号还是with editor

157 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2229648, encodeId=a7a72229648e0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：自身免疫性疾病 经验分享：投的review，非常快，体验感很好。7.16号投稿，7.22号送审，7.30号送审结束，两个审稿人意见，8.6号大修，9.3号提交response，9.8号返修来自两个审稿人的小修意见，9.12号提交response，9.13号回复小修，9.24号提交response，9.26号接受，当天proof，9.28号见刊。神速~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb785144048, createdName=14681332m54(暂无昵称), createdTime=Mon Oct 07 14:15:00 CST 2024, time=2024-10-07, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2231090, encodeId=268b2231090f8, content=请问各位大佬，这个期刊with editor 后状态变成decision in process 是不是就是要拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=461a2103235, createdName=1521f6f9dcm, createdTime=Tue Oct 15 19:39:47 CST 2024, time=2024-10-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2197439, encodeId=fa4c219e4396e, content=偏重的研究方向：哮喘;巨噬细胞 经验分享：来积攒人品。3月21日提交，3月22日with editor ，4月6日decision in process,目前还是decision in process, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fed15185369, createdName=14706479m35(暂无昵称), createdTime=Mon Apr 08 19:19:48 CST 2024, time=2024-04-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2200114, encodeId=d48a2200114a5, content=4.4号投稿，4.5号with editor 4.18号还是with editor , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e884788237, createdName=mxy268133mxy, createdTime=Wed Apr 24 12:19:18 CST 2024, time=2024-04-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1217049, encodeId=239f121e049dd, content=有没有人可以分享一下投稿进程？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a9b85535861, createdName=Mis 吴, createdTime=Thu May 05 14:06:39 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192591, encodeId=259b219259102, content=偏重的研究方向：免疫 经验分享：2024.03.08 submitted to journal 2024.03.08 with editor 投稿时忘记上传WB 的原始图片PDF了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Mar 11 15:27:07 CST 2024, time=2024-03-11, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2193998, encodeId=f568219399892, content=提交到期刊近20天没有变化，杂志首页却介绍首个决定5天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/n4IYDdvYfkjeLr8oiaPal0dQa93Zgia4eCSXxEJrEoviaPdbED0F1HbgT84Xfl8v7mTjsHNkG5sK8fxVjBrU4N8XQ/132, createdBy=00212440140, createdName=ms3236964720522021, createdTime=Tue Mar 19 08:56:09 CST 2024, time=2024-03-19, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2178587, encodeId=89a521e85875b, content=请问各位大佬，jornal of autoimmunity投稿对摘要和全文没有字数要求吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7be6461276, createdName=ms3000000202046104, createdTime=Mon Jan 01 14:08:20 CST 2024, time=2024-01-01, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2174377, encodeId=290a21e4377e3, content=有哪位大神可以告知一下，为什么投稿第二步，attach files 总过不去，也上传文件了，就是不行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e759104536, createdName=ms7000001739408141, createdTime=Tue Dec 12 07:08:18 CST 2023, time=2023-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=569627, encodeId=b9dd56962ea6, content=综述要约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce9a2150313, createdName=138200c9a8m, createdTime=Wed Apr 17 00:00:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]

2022-05-05 Mis 吴

有没有人可以分享一下投稿进程？谢谢

239 3 举报

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2229648, encodeId=a7a72229648e0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：自身免疫性疾病 经验分享：投的review，非常快，体验感很好。7.16号投稿，7.22号送审，7.30号送审结束，两个审稿人意见，8.6号大修，9.3号提交response，9.8号返修来自两个审稿人的小修意见，9.12号提交response，9.13号回复小修，9.24号提交response，9.26号接受，当天proof，9.28号见刊。神速~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb785144048, createdName=14681332m54(暂无昵称), createdTime=Mon Oct 07 14:15:00 CST 2024, time=2024-10-07, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2231090, encodeId=268b2231090f8, content=请问各位大佬，这个期刊with editor 后状态变成decision in process 是不是就是要拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=461a2103235, createdName=1521f6f9dcm, createdTime=Tue Oct 15 19:39:47 CST 2024, time=2024-10-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2197439, encodeId=fa4c219e4396e, content=偏重的研究方向：哮喘;巨噬细胞 经验分享：来积攒人品。3月21日提交，3月22日with editor ，4月6日decision in process,目前还是decision in process, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fed15185369, createdName=14706479m35(暂无昵称), createdTime=Mon Apr 08 19:19:48 CST 2024, time=2024-04-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2200114, encodeId=d48a2200114a5, content=4.4号投稿，4.5号with editor 4.18号还是with editor , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e884788237, createdName=mxy268133mxy, createdTime=Wed Apr 24 12:19:18 CST 2024, time=2024-04-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1217049, encodeId=239f121e049dd, content=有没有人可以分享一下投稿进程？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a9b85535861, createdName=Mis 吴, createdTime=Thu May 05 14:06:39 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192591, encodeId=259b219259102, content=偏重的研究方向：免疫 经验分享：2024.03.08 submitted to journal 2024.03.08 with editor 投稿时忘记上传WB 的原始图片PDF了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Mar 11 15:27:07 CST 2024, time=2024-03-11, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2193998, encodeId=f568219399892, content=提交到期刊近20天没有变化，杂志首页却介绍首个决定5天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/n4IYDdvYfkjeLr8oiaPal0dQa93Zgia4eCSXxEJrEoviaPdbED0F1HbgT84Xfl8v7mTjsHNkG5sK8fxVjBrU4N8XQ/132, createdBy=00212440140, createdName=ms3236964720522021, createdTime=Tue Mar 19 08:56:09 CST 2024, time=2024-03-19, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2178587, encodeId=89a521e85875b, content=请问各位大佬，jornal of autoimmunity投稿对摘要和全文没有字数要求吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7be6461276, createdName=ms3000000202046104, createdTime=Mon Jan 01 14:08:20 CST 2024, time=2024-01-01, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2174377, encodeId=290a21e4377e3, content=有哪位大神可以告知一下，为什么投稿第二步，attach files 总过不去，也上传文件了，就是不行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e759104536, createdName=ms7000001739408141, createdTime=Tue Dec 12 07:08:18 CST 2023, time=2023-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=569627, encodeId=b9dd56962ea6, content=综述要约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce9a2150313, createdName=138200c9a8m, createdTime=Wed Apr 17 00:00:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]

2024-03-11 1487e742m42(暂无昵称) 来自内蒙古

偏重的研究方向：免疫
经验分享：2024.03.08 submitted to journal
2024.03.08 with editor
投稿时忘记上传WB 的原始图片PDF了。。。

214 10 举报

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=2229648, encodeId=a7a72229648e0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：自身免疫性疾病 经验分享：投的review，非常快，体验感很好。7.16号投稿，7.22号送审，7.30号送审结束，两个审稿人意见，8.6号大修，9.3号提交response，9.8号返修来自两个审稿人的小修意见，9.12号提交response，9.13号回复小修，9.24号提交response，9.26号接受，当天proof，9.28号见刊。神速~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb785144048, createdName=14681332m54(暂无昵称), createdTime=Mon Oct 07 14:15:00 CST 2024, time=2024-10-07, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2231090, encodeId=268b2231090f8, content=请问各位大佬，这个期刊with editor 后状态变成decision in process 是不是就是要拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=461a2103235, createdName=1521f6f9dcm, createdTime=Tue Oct 15 19:39:47 CST 2024, time=2024-10-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2197439, encodeId=fa4c219e4396e, content=偏重的研究方向：哮喘;巨噬细胞 经验分享：来积攒人品。3月21日提交，3月22日with editor ，4月6日decision in process,目前还是decision in process, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fed15185369, createdName=14706479m35(暂无昵称), createdTime=Mon Apr 08 19:19:48 CST 2024, time=2024-04-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2200114, encodeId=d48a2200114a5, content=4.4号投稿，4.5号with editor 4.18号还是with editor , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e884788237, createdName=mxy268133mxy, createdTime=Wed Apr 24 12:19:18 CST 2024, time=2024-04-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1217049, encodeId=239f121e049dd, content=有没有人可以分享一下投稿进程？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a9b85535861, createdName=Mis 吴, createdTime=Thu May 05 14:06:39 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192591, encodeId=259b219259102, content=偏重的研究方向：免疫 经验分享：2024.03.08 submitted to journal 2024.03.08 with editor 投稿时忘记上传WB 的原始图片PDF了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Mar 11 15:27:07 CST 2024, time=2024-03-11, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2193998, encodeId=f568219399892, content=提交到期刊近20天没有变化，杂志首页却介绍首个决定5天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/n4IYDdvYfkjeLr8oiaPal0dQa93Zgia4eCSXxEJrEoviaPdbED0F1HbgT84Xfl8v7mTjsHNkG5sK8fxVjBrU4N8XQ/132, createdBy=00212440140, createdName=ms3236964720522021, createdTime=Tue Mar 19 08:56:09 CST 2024, time=2024-03-19, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2178587, encodeId=89a521e85875b, content=请问各位大佬，jornal of autoimmunity投稿对摘要和全文没有字数要求吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7be6461276, createdName=ms3000000202046104, createdTime=Mon Jan 01 14:08:20 CST 2024, time=2024-01-01, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2174377, encodeId=290a21e4377e3, content=有哪位大神可以告知一下，为什么投稿第二步，attach files 总过不去，也上传文件了，就是不行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e759104536, createdName=ms7000001739408141, createdTime=Tue Dec 12 07:08:18 CST 2023, time=2023-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=569627, encodeId=b9dd56962ea6, content=综述要约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce9a2150313, createdName=138200c9a8m, createdTime=Wed Apr 17 00:00:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]

2024-03-19 ms3236964720522021 来自陕西省

提交到期刊近20天没有变化，杂志首页却介绍首个决定5天。

202 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2229648, encodeId=a7a72229648e0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：自身免疫性疾病 经验分享：投的review，非常快，体验感很好。7.16号投稿，7.22号送审，7.30号送审结束，两个审稿人意见，8.6号大修，9.3号提交response，9.8号返修来自两个审稿人的小修意见，9.12号提交response，9.13号回复小修，9.24号提交response，9.26号接受，当天proof，9.28号见刊。神速~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb785144048, createdName=14681332m54(暂无昵称), createdTime=Mon Oct 07 14:15:00 CST 2024, time=2024-10-07, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2231090, encodeId=268b2231090f8, content=请问各位大佬，这个期刊with editor 后状态变成decision in process 是不是就是要拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=461a2103235, createdName=1521f6f9dcm, createdTime=Tue Oct 15 19:39:47 CST 2024, time=2024-10-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2197439, encodeId=fa4c219e4396e, content=偏重的研究方向：哮喘;巨噬细胞 经验分享：来积攒人品。3月21日提交，3月22日with editor ，4月6日decision in process,目前还是decision in process, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fed15185369, createdName=14706479m35(暂无昵称), createdTime=Mon Apr 08 19:19:48 CST 2024, time=2024-04-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2200114, encodeId=d48a2200114a5, content=4.4号投稿，4.5号with editor 4.18号还是with editor , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e884788237, createdName=mxy268133mxy, createdTime=Wed Apr 24 12:19:18 CST 2024, time=2024-04-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1217049, encodeId=239f121e049dd, content=有没有人可以分享一下投稿进程？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a9b85535861, createdName=Mis 吴, createdTime=Thu May 05 14:06:39 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192591, encodeId=259b219259102, content=偏重的研究方向：免疫 经验分享：2024.03.08 submitted to journal 2024.03.08 with editor 投稿时忘记上传WB 的原始图片PDF了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Mar 11 15:27:07 CST 2024, time=2024-03-11, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2193998, encodeId=f568219399892, content=提交到期刊近20天没有变化，杂志首页却介绍首个决定5天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/n4IYDdvYfkjeLr8oiaPal0dQa93Zgia4eCSXxEJrEoviaPdbED0F1HbgT84Xfl8v7mTjsHNkG5sK8fxVjBrU4N8XQ/132, createdBy=00212440140, createdName=ms3236964720522021, createdTime=Tue Mar 19 08:56:09 CST 2024, time=2024-03-19, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2178587, encodeId=89a521e85875b, content=请问各位大佬，jornal of autoimmunity投稿对摘要和全文没有字数要求吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7be6461276, createdName=ms3000000202046104, createdTime=Mon Jan 01 14:08:20 CST 2024, time=2024-01-01, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2174377, encodeId=290a21e4377e3, content=有哪位大神可以告知一下，为什么投稿第二步，attach files 总过不去，也上传文件了，就是不行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e759104536, createdName=ms7000001739408141, createdTime=Tue Dec 12 07:08:18 CST 2023, time=2023-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=569627, encodeId=b9dd56962ea6, content=综述要约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce9a2150313, createdName=138200c9a8m, createdTime=Wed Apr 17 00:00:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]

2024-01-01 ms3000000202046104 来自吉林省

请问各位大佬，jornal of autoimmunity投稿对摘要和全文没有字数要求吗？

156 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2229648, encodeId=a7a72229648e0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：自身免疫性疾病 经验分享：投的review，非常快，体验感很好。7.16号投稿，7.22号送审，7.30号送审结束，两个审稿人意见，8.6号大修，9.3号提交response，9.8号返修来自两个审稿人的小修意见，9.12号提交response，9.13号回复小修，9.24号提交response，9.26号接受，当天proof，9.28号见刊。神速~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb785144048, createdName=14681332m54(暂无昵称), createdTime=Mon Oct 07 14:15:00 CST 2024, time=2024-10-07, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2231090, encodeId=268b2231090f8, content=请问各位大佬，这个期刊with editor 后状态变成decision in process 是不是就是要拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=461a2103235, createdName=1521f6f9dcm, createdTime=Tue Oct 15 19:39:47 CST 2024, time=2024-10-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2197439, encodeId=fa4c219e4396e, content=偏重的研究方向：哮喘;巨噬细胞 经验分享：来积攒人品。3月21日提交，3月22日with editor ，4月6日decision in process,目前还是decision in process, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fed15185369, createdName=14706479m35(暂无昵称), createdTime=Mon Apr 08 19:19:48 CST 2024, time=2024-04-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2200114, encodeId=d48a2200114a5, content=4.4号投稿，4.5号with editor 4.18号还是with editor , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e884788237, createdName=mxy268133mxy, createdTime=Wed Apr 24 12:19:18 CST 2024, time=2024-04-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1217049, encodeId=239f121e049dd, content=有没有人可以分享一下投稿进程？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a9b85535861, createdName=Mis 吴, createdTime=Thu May 05 14:06:39 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192591, encodeId=259b219259102, content=偏重的研究方向：免疫 经验分享：2024.03.08 submitted to journal 2024.03.08 with editor 投稿时忘记上传WB 的原始图片PDF了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Mar 11 15:27:07 CST 2024, time=2024-03-11, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2193998, encodeId=f568219399892, content=提交到期刊近20天没有变化，杂志首页却介绍首个决定5天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/n4IYDdvYfkjeLr8oiaPal0dQa93Zgia4eCSXxEJrEoviaPdbED0F1HbgT84Xfl8v7mTjsHNkG5sK8fxVjBrU4N8XQ/132, createdBy=00212440140, createdName=ms3236964720522021, createdTime=Tue Mar 19 08:56:09 CST 2024, time=2024-03-19, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2178587, encodeId=89a521e85875b, content=请问各位大佬，jornal of autoimmunity投稿对摘要和全文没有字数要求吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7be6461276, createdName=ms3000000202046104, createdTime=Mon Jan 01 14:08:20 CST 2024, time=2024-01-01, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2174377, encodeId=290a21e4377e3, content=有哪位大神可以告知一下，为什么投稿第二步，attach files 总过不去，也上传文件了，就是不行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e759104536, createdName=ms7000001739408141, createdTime=Tue Dec 12 07:08:18 CST 2023, time=2023-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=569627, encodeId=b9dd56962ea6, content=综述要约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce9a2150313, createdName=138200c9a8m, createdTime=Wed Apr 17 00:00:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]

2023-12-12 ms7000001739408141 来自北京

有哪位大神可以告知一下，为什么投稿第二步，attach files 总过不去，也上传文件了，就是不行

157 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2229648, encodeId=a7a72229648e0, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：自身免疫性疾病 经验分享：投的review，非常快，体验感很好。7.16号投稿，7.22号送审，7.30号送审结束，两个审稿人意见，8.6号大修，9.3号提交response，9.8号返修来自两个审稿人的小修意见，9.12号提交response，9.13号回复小修，9.24号提交response，9.26号接受，当天proof，9.28号见刊。神速~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb785144048, createdName=14681332m54(暂无昵称), createdTime=Mon Oct 07 14:15:00 CST 2024, time=2024-10-07, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2231090, encodeId=268b2231090f8, content=请问各位大佬，这个期刊with editor 后状态变成decision in process 是不是就是要拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=461a2103235, createdName=1521f6f9dcm, createdTime=Tue Oct 15 19:39:47 CST 2024, time=2024-10-15, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2197439, encodeId=fa4c219e4396e, content=偏重的研究方向：哮喘;巨噬细胞 经验分享：来积攒人品。3月21日提交，3月22日with editor ，4月6日decision in process,目前还是decision in process, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=171, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fed15185369, createdName=14706479m35(暂无昵称), createdTime=Mon Apr 08 19:19:48 CST 2024, time=2024-04-08, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2200114, encodeId=d48a2200114a5, content=4.4号投稿，4.5号with editor 4.18号还是with editor , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e884788237, createdName=mxy268133mxy, createdTime=Wed Apr 24 12:19:18 CST 2024, time=2024-04-24, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1217049, encodeId=239f121e049dd, content=有没有人可以分享一下投稿进程？谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=239, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a9b85535861, createdName=Mis 吴, createdTime=Thu May 05 14:06:39 CST 2022, time=2022-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2192591, encodeId=259b219259102, content=偏重的研究方向：免疫 经验分享：2024.03.08 submitted to journal 2024.03.08 with editor 投稿时忘记上传WB 的原始图片PDF了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ffcd5307805, createdName=1487e742m42(暂无昵称), createdTime=Mon Mar 11 15:27:07 CST 2024, time=2024-03-11, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2193998, encodeId=f568219399892, content=提交到期刊近20天没有变化，杂志首页却介绍首个决定5天。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/n4IYDdvYfkjeLr8oiaPal0dQa93Zgia4eCSXxEJrEoviaPdbED0F1HbgT84Xfl8v7mTjsHNkG5sK8fxVjBrU4N8XQ/132, createdBy=00212440140, createdName=ms3236964720522021, createdTime=Tue Mar 19 08:56:09 CST 2024, time=2024-03-19, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2178587, encodeId=89a521e85875b, content=请问各位大佬，jornal of autoimmunity投稿对摘要和全文没有字数要求吗？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7be6461276, createdName=ms3000000202046104, createdTime=Mon Jan 01 14:08:20 CST 2024, time=2024-01-01, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2174377, encodeId=290a21e4377e3, content=有哪位大神可以告知一下，为什么投稿第二步，attach files 总过不去，也上传文件了，就是不行, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e759104536, createdName=ms7000001739408141, createdTime=Tue Dec 12 07:08:18 CST 2023, time=2023-12-12, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=569627, encodeId=b9dd56962ea6, content=综述要约稿吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce9a2150313, createdName=138200c9a8m, createdTime=Wed Apr 17 00:00:00 CST 2019, time=2019-04-17, status=1, ipAttribution=)]

2019-04-17 138200c9a8m

综述要约稿吗？

420 2 举报

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务